The potential to therapeutically target aberrant RBP activities in myeloma has been demonstrated by Marchesini et al. The investigators showed that genomically unstable and aggressive myelomas carrying the 1q21 amplification have acquired dependency on the 1q21 induced overexpression of the RBP ILF2 (interleukin enhancer binding factor 2) (Marchesini et al., 2017b). Here, ILF2 is linked to plasma cell myeloma.